Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Previous meta-analyses of fluoxetine as an antidepressant have many methodological problems, including diagnosis of major depression, validity of outcome measures and lack of intention-to-treat analyses. Aims: To provide an estimate of the effect of fluoxetine compared with placebo and tricyclic antidepressants (TCAs), and to investigate reasons for early discontinuation from acute treatment. Method: Randomised trials were analysed using both intention-to-treat, efficacy and end-point. Results: Fluoxetine was superior to placebo but effect size was low. In trials comparing fluoxetine v. TCA, the results for all trials and for the USA trials showed a trend in favour of fluoxetine. Those for the non-USA trials showed a trend in favour of TCA. When combined, the results showed that significantly fewer patients on fluoxetine discontinued treatment because of adverse events. Conclusion: Fluoxetine is superior to placebo, irrespective of the analytical approach use, whereas the results obtained v. TCAs depend on the approach used. Hence, the results should be interpreted in this light.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Secondary, and Meta-Analysis of Research
GLASS, G. V. (1976) · Educational Researcher · doi:10.3102/0013189x005010003 · Cited by 4,890
Statistical Power Analysis for the Behavioral Sciences
(1977) · doi:10.1016/c2013-0-10517-x · Cited by 2,457
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A., & Mason, J. (1993) · BMJ · doi:10.1136/bmj.306.6879.683 · Cited by 399
Cited by
Golden, R. N., Gaynes, B. N., Ekstrom, R. D., Hamer, R. M., Jacobsen, F. M., Suppes, T., Wisner, K. L., & Nemeroff, C. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.656 · Cited by 896
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Similarly, numerous double-blind controlled trials have demonstrated superior effi cacy of the SSRI compared to placebo (AHCPR 1999; Bech et al. 2000; Khan et al. 2000; Mace and Taylor 2000).”
BackgroundPeet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 614
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Gunnell, D., Saperia, J., & Ashby, D. (2005) · BMJ · doi:10.1136/bmj.330.7488.385 · Cited by 387
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329
Schiffer, F., Johnston, A. L., Ravichandran, C., Polcari, A., Teicher, M. H., Webb, R. H., & Hamblin, M. R. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-46 · Cited by 317
Interventions to improve return to work in depressed people
Nieuwenhuijsen, K., Faber, B., Verbeek, J. H., Neumeyer-Gromen, A., Hees, H. L., Verhoeven, A. C., van der Feltz-Cornelis, C. M., & Bültmann, U. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006237.pub3 · Cited by 299
Measuring depression: comparison and integration of three scales in the GENDEP study
Uher, R., Farmer, A., Maier, W., Rietschel, M., Hauser, J., Marusic, A., Mors, O., Elkin, A., Williamson, R. J., Schmael, C., et al. (2008) · Psychological Medicine · doi:10.1017/s0033291707001730 · Cited by 293
Carrozzino, D., Patierno, C., Fava, G. A., & Guidi, J. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506879 · Cited by 263
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Patel, V., Chisholm, D., Rabe-Hesketh, S., Dias-Saxena, F., Andrew, G., & Mann, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12119-8 · Cited by 217
Psychotherapy for depression among incurable cancer patients
Akechi, T., Okuyama, T., Onishi, J., Morita, T., & Furukawa, T. A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005537.pub2 · Cited by 198
RetractedPrado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Cultural factors and international epidemiology
Patel, V. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.33 · Cited by 179
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457131 · Cited by 134
Self-citationTrends in service use and treatment for mental disorders in adults throughout Great Britain
Brugha, T. S., Bebbington, P. E., Singleton, N., Melzer, D., Jenkins, R., Lewis, G., Farrell, M., Bhugra, D., Lee, A., & Meltzer, H. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.5.378 · Cited by 114
“For example, if 11% more of those with mental disorder received antidepressants and the number needed to treat in order for one patient to benefit was about 7 (Bech et al, 2000), only 1.5% more would improve as a result of medication alone.”
BackgroundInfluentialAntidepressants for people with both schizophrenia and depression
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002305 · Cited by 92
Tran, P., Skolnick, P., Czobor, P., Huang, N. Y., Bradshaw, M., McKinney, A., & Fava, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.003 · Cited by 81
Retz, W., Rösler, M., Ose, C., Scherag, A., Alm, B., Philipsen, A., Fischer, R., Ammer, R., & The Study Group (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.540257 · Cited by 79
van der Lem, R., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330890 · Cited by 63
Østergaard, S. D., Bech, P., & Miskowiak, K. W. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.047 · Cited by 55
Self-citationFujisawa, D., Nakagawa, A., Tajima, M., Sado, M., Kikuchi, T., Hanaoka, M., & Ono, Y. (2010) · BMC Research Notes · doi:10.1186/1756-0500-3-160 · Cited by 39
“The cutoff point for remission was defined as an endpoint BDI-II score of 13 or less [16], and treatment response was defined as a reduction of 50% on the BDI-II [22].”
MethodFountoulakis, K. N., & Möller, H.-J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111421969 · Cited by 30
“During the last decade, the usefulness of antidepressants in clinical practice has been questioned, with meta-analytic studies suggesting their effect size is rather small (Bech et al., 2000; Ghaemi, 2008; Moncrieff et al., 2004).”
Background(2008) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 26
Lin, C. ‐., Yang, W. ‐., Chen, C. ‐., & Cai, W. ‐. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13183 · Cited by 8
(2000) · doi:10.1002/1520-6394(2000)12:1+<2::aid-da2>3.0.co;2-4
Metadata
- Authors
- Bech, P., Cialdella, P., Haugh, M. C., Birkett, M. A., Hours, A., Boissel, J. P., & Tollefson, G. D.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2000-05
- Volume
- 176
- Issue
- 5
- Pages
- 421-428
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1996114361
- Cited by
- 157
- References
- 4
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.